Study


Lilly’s Bamlanivimab and Etesevimab

On March 10, Eli Lilly and Company announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating bamlanivimab (LY-CoV555) 700 mg and…








COVID Studies Concerns

Two of the world’s heading pharmaceutical journals on Tuesday showed concern about potential flaws in the data and covid studies provided by a little company…


COVID-19: Patients Improvements

Systemic anticoagulation may be correlated with enhanced outcomes among COVID-19 patients, according to an analysis letter published May 6 in the Journal of the American…